Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cellectis S.A. (CLLS : NSDQ)

• Company Description    Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. Number of Employees: 222

• Price / Volume Information    Yesterday's Closing Price: $1.55 Daily Weekly Monthly 20 Day Moving Average: 50,236 shares Shares Outstanding: 55.58 (millions) Market Capitalization: $86.15 (millions) Beta: 2.91 52 Week High: $2.43 52 Week Low: $1.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.16% 2.27% 12 Week 27.26% 2.31% Year To Date -13.89% -18.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8 RUE DE LA CROIX JARRY - PARIS LLE-DE-FRANCE,I0 75013 FRA ph: 33-1-81-69-16-00 fax: 33-1-81-69-16-06 investors@cellectis.com http://www.cellectis.com

• General Corporate Information    Officers Andre Choulika - Chief Executive Officer and Co-Founder Jean-Pierre Garnier - Chairman of the Board and Director Arthur Stril - Chief Financial Officer & Chief Business Officer Laurent Arthaud - Director Pierre Bastid - Director Peer Information Cellectis S.A. (CORR.) Cellectis S.A. (RSPI) Cellectis S.A. (CGXP) Cellectis S.A. (BGEN) Cellectis S.A. (GTBP) Cellectis S.A. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15117K103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 55.58 Most Recent Split Date: (:1) Beta: 2.91 Market Capitalization: $86.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.74 Price/Cash Flow: - Price / Sales: 1.18 EPS Growth vs. Year Ago Period: -20.00% vs. Previous Quarter: -12.50% Sales Growth vs. Year Ago Period: 85.12% vs. Previous Quarter: -63.79% ROE 06/30/25 - - 03/31/25 - -62.55 12/31/24 - -46.73 ROA 06/30/25 - - 03/31/25 - -21.19 12/31/24 - -15.15 Current Ratio 06/30/25 - - 03/31/25 - 1.67 12/31/24 - 1.73 Quick Ratio 06/30/25 - - 03/31/25 - 1.67 12/31/24 - 1.73 Operating Margin 06/30/25 - - 03/31/25 - -112.83 12/31/24 - -86.77 Net Margin 06/30/25 - - 03/31/25 - -114.82 12/31/24 - -88.92 Pre-Tax Margin 06/30/25 - - 03/31/25 - -82.79 12/31/24 - -74.69 Book Value 06/30/25 - - 03/31/25 - 2.09 12/31/24 - 2.36 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.44 12/31/24 - 0.39 Debt-to-Capital 06/30/25 - - 03/31/25 - 30.52 12/31/24 - 27.97

Powered by Zacks Investment Research ©